Clinical Trials on Carcinoma, Neuroendocrine

Total 26363 results

Xiang Lu

Recruiting

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinomas | Resectable Head and Neck Squamous-cell Carcinoma

China
Xian-Jun Yu

Not yet recruiting

Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis

Neuroendocrine Neoplasm

China
University Medical Center Groningen

Completed

Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor (WIN)

Neuroendocrine Tumor

Netherlands
Thomas Hope

Completed

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

Neuroendocrine Tumor

United States
Ipsen

Terminated

A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours (PRELUDE)

Neuroendocrine Tumours

United Kingdom, France, Germany, Australia, Italy
Samsung Medical Center

Completed

Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Neuroendocrine Tumor

Korea, Republic of
Nuclear Medicine Consultants, Inc.

Unknown

Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours

Neuroendocrine Tumor

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...

Completed

Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

Neuroendocrine Tumor

United States
Pfizer

Terminated

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Metastatic Pancreatic Adenocarcinoma | BRAF Mutated Melanoma

United States, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shenzhen Sixth People's Hospital; Zhongshan People's Hospital, Guangdong, China

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

Head and Neck Squamous Cell Carcinomas

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Head and Neck Squamous Cell Carcinomas

China
Assistance Publique - Hôpitaux de Paris

Completed

Multipolar Radiofrequency Ablation for Hepatocellular Carcinoma Using Extra Nodular Versus Intranodular Technique (ARMCENVIN)

Hepatocellular Carcinomas

France
Istituto Scientifico Romagnolo per lo Studio e...

Unknown

Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2 (IL2HD)

Metastatic Renal Cell Cancer | Malignant Melanoma, Metastatic

Italy
GI Innovation, Inc.
Merck Sharp & Dohme LLC

Recruiting

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Melanoma | Sarcoma | Renal Cell Carcinoma | Cervical Cancer | Urinary Bladder Cancer | Vulvar Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Vaginal Cancer | Microsatellite Stable...

Korea, Republic of, United States
European Institute of Oncology

Recruiting

Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients (TAPIOCA)

Neuroendocrine Neoplasm

Italy
Biotheus Inc.

Recruiting

A Study of PM8002 Injection in Combination With Chemotherapy in Patients With NEN

Neuroendocrine Neoplasm

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor

Neuroendocrine Tumor

China
Radiomedix, Inc.
Orano Med LLC

Recruiting

Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET

Neuroendocrine Tumor

United States
University Medical Center Groningen

Completed

Optimal Feeding for NET Patients (DIVIT-pilot)

Neuroendocrine Tumor

Netherlands
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Neuroendocrine Neoplasm

United States
Jagiellonian University
Medical University Innsbruck; University Medical Centre Ljubljana; University... and other collaborators

Completed

Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms (TECANT)

Neuroendocrine Tumors

Austria, Poland, Slovenia
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Neuroendocrine Tumours

Spain
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. (ATLANT)

Neuroendocrine Tumours

Italy
Xiangya Hospital of Central South University

Unknown

A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms

Neuroendocrine Neoplasm

China
Peking University

Recruiting

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC

Neuroendocrine Neoplasm

China
Fudan University
D1 Medical Technology (Shanghai) Co., Ltd, China

Recruiting

Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm

Neuroendocrine Neoplasm

China
Tine Gregersen, MD

Recruiting

Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients (DOBATOC)

Neuroendocrine Neoplasm

Denmark
University Medical Center Groningen

Completed

DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor

Neuroendocrine Tumor

Netherlands
University Medical Center Groningen

Completed

Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study (VIDEO-NET)

Neuroendocrine Tumor

Netherlands
Novartis Pharmaceuticals

Completed

Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)

Neuroendocrine Tumor

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Unknown

Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors

Neuroendocrine Tumor

United States
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Completed

Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

PANCREAS | Neuroendocrine

United States
Hadassah Medical Organization

Unknown

Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors

Neuroendocrine Tumor

Israel
Peking University

Not yet recruiting

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

China
Wren Laboratories LLC

Active, not recruiting

Surgical Intervention and the NETest (NETest_Sx)

Neuroendocrine Tumor | Gastroenteropancreatic

Italy
University Hospital, Toulouse

Active, not recruiting

Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor (GENEBIOLuNET)

Midgut Neuroendocrine Tumors

France
Istituto Scientifico Romagnolo per lo Studio e...

Active, not recruiting

Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors (LUNET)

Neuroendocrine Tumors

Italy
Ipsen

Completed

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET (SONNET)

Gastroenteropancreatic Neuroendocrine Tumors

Germany, Austria
Uppsala University

Unknown

Biomarker Study in Pancreatic Neuroendocrine Tumours (PROGRESS)

Neuroendocrine Tumors

Sweden
Cancer Institute and Hospital, Chinese Academy...

Unknown

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

Extrapancreatic Neuroendocrine Tumor

China
Cytovation AS
Merck Sharp & Dohme LLC

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (Catalyst)

Advanced Breast Cancer | Advanced Melanoma | Advanced Head and Neck Squamous Cell Carcinoma

United States, France, Italy, Spain, Netherlands
University Health Network, Toronto
Princess Margaret Hospital, Canada

Completed

Ultrasound Biomicroscopy - Apoptosis

Melanoma | Lymphoma | Lymphoma, Non-Hodgkin | Carcinoma, Basal Cell

Canada
Novartis Pharmaceuticals

Completed

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Neuroendocrine Tumors | Carcinoma, Large Cell

Germany
University of Florida
Monteris Medical

Terminated

LITT and Pembrolizumab in Recurrent Brain Metastasis (TORCH)

Melanoma | Primary Mediastinal Large B-Cell Lymphoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Esophageal Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Cancer | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Merkel Cell Carcinoma | Brain Metastases, Adult | Renal Cell... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

Breast Cancer | Pancreatic Cancer | Lung Cancer | Rectal Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer | Colon Cancer | Gastrointestinal Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer | Thyroid Gland Medullary Carcinoma | Liver and Intrahepatic Biliary Tract Cancer

United States
Fate Therapeutics

Terminated

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumor | Small-cell Lung Cancer | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions

United States
Shanghai Changzheng Hospital

Not yet recruiting

A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy

Advanced Solid Tumors With Neuroendocrine Differentiation
Centre Leon Berard

Not yet recruiting

Tobacco, Alcohol and Cancerization of the Oral Mucosa (TACO) (TACO)

Oral Squamous Cell Carcinomas

France
Hospital of Stomatology, Wuhan University

Recruiting

The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma

Clinical IVb Stage Oral Squamous Cell Carcinomas Patients

China
Merck Sharp & Dohme LLC

Completed

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Melanoma | Renal Cell Carcinoma | Breast Cancer | Prostate Cancer | Bladder Carcinoma | Colon Carcinoma | Non-Small Cell Lung Carcinoma | Upper GI Tract Carcinoma

Clinical Trials on Carcinoma, Neuroendocrine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations